HSDB 1430 en es it fr

HSDB 1430 Brand names, HSDB 1430 Analogs

HSDB 1430 Brand Names Mixture

  • No information avaliable

HSDB 1430 Chemical_Formula


HSDB 1430 RX_link

No information avaliable

HSDB 1430 fda sheet

HSDB 1430 msds (material safety sheet)


HSDB 1430 Synthesis Reference

No information avaliable

HSDB 1430 Molecular Weight

133.104 g/mol

HSDB 1430 Melting Point

230 oC

HSDB 1430 H2O Solubility

4.5 g/l

HSDB 1430 State


HSDB 1430 LogP

-0.67 +/- 0.36

HSDB 1430 Dosage Forms

Capsules and powder

HSDB 1430 Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

HSDB 1430 Pharmacology

L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.

HSDB 1430 Absorption

Absorbed from the small intestine by an active transport process

HSDB 1430 side effects and Toxicity

Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.

HSDB 1430 Patient Information

No information avaliable

HSDB 1430 Organisms Affected

Humans and other mammals